Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clementia Pharmaceuticals
Biotech
Ipsen's rare disease candidate rejected after mounting delays
Ipsen is racing to answer the FDA's questions regarding its rare disease med palovarotene after the agency rejected the company's application.
Max Bayer
Dec 27, 2022 10:44am
Ipsen's rare disease med palovarotene faces another delay
Oct 25, 2022 4:03pm
Congruence to build team of 'drug hunters' with $50M funding
Feb 8, 2022 8:00am
Ipsen scraps pivotal trial as partial clinical hold drags on
Mar 26, 2020 8:45am
Regeneron's rare bone disease drug delivers in phase 2
Jan 9, 2020 10:38am
Ipsen strikes $1.3B Clementia buyout to boost rare disease unit
Feb 25, 2019 10:45am